Background: Oxaliplatin-based chemotherapy can cause hepatic sinusoidal injury (HSI), portal hypertension, and splenic sequestration of platelets. Evidence suggests that bevacizumab may protect against HSI. Methods: Two cohorts of metastatic colorectal cancer (CRC) were analyzed: a nonrandomized exploratory cohort of 184 patients treated at a single institution from 2003 to 2010 and a confirmatory cohort of 200 patients from a multi-institutional randomized trial (NO16966). All patients were treated with frontline fluoropyrimidine and oxaliplatin with or without bevacizumab. Changes in splenic volumes and platelet counts were compared by treatment, two-sided log-rank test. Results: In the exploratory cohort, the bevacizumab-treated patients (n = 138) compared with the nonbevacizumab-treated patients (n = 46) demonstrated a longer median time to splenic enlargement (<30%, P =.02) and reduced rate of thrombocytopenia (<150000/mm3, P =.04). In the confirmatory cohort (106 bevacizumab arm and 94 placebo arm), the median time to a spleen enlargement of 30% or more was 7.6 vs 5.4 (P =.01), and six-month cumulative incidence of thrombocytopenia (platelets > 100 000/mm3) was 19% vs 51% (P
CITATION STYLE
Overman, M. J., Ferrarotto, R., Raghav, K., George, B., Qiao, W., Machado, K. K., … Kopetz, S. (2018). The addition of bevacizumab to oxaliplatin-based chemotherapy: Impact upon hepatic sinusoidal injury and thrombocytopenia. Journal of the National Cancer Institute, 110(8), 888–894. https://doi.org/10.1093/jnci/djx288
Mendeley helps you to discover research relevant for your work.